Feng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Feng Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Shuyong Yao
Department of Pharmacy, Affiliated Guangji Hospital of Soochow University, Suzhou, Jiangsu, China
2 shared publications - Bi-Kui Zhang
Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha 410011, China
1 shared publication - Da-Xiong Xiang
Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China
1 shared publication - Da-Xiong Xiang
Institute of Clinical Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
1 shared publication - Guozhong Gong
Department of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, 410001 Hunan, China; FuRong Laboratory, Changsha, 410078 Hunan, China; Clinical Medical Research Center for Viral Hepatitis of Hunan Province, Changsha, 410001 Hunan, China
1 shared publication - Hoan Linh Banh
University of Alberta
1 shared publication
Latest Publications
- Open Access
- 20 September 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (9) , 1130
Predictors of Voriconazole Trough Concentrations in Patients with Child–Pugh Class C Cirrhosis: A Prospective Study
This prospective observational study aimed to clinically describe voriconazole administrations and trough concentrations in patients with Child–Pugh class C and to investigate the variability of trough concentration. A total of 144 voriconazole trough concentrations from 43 Child–Pugh class C patients were analyzed. The majority of patients (62.8%) received adjustments. The repeated measured trough concentration was higher than the first and final ones generally (median, 4.33 vs. 2.99, 3.90 mg/L). Eight patients with ideal initial concentrations later got supratherapeutic with no adjusted daily dose, implying accumulation. There was a significant difference in concentrations among the six groups by daily dose (p = 0.006). The bivariate correlation analysis showed that sex, CYP2C19 genotyping, daily dose, prothrombin time activity, international normalized ratio, platelet, and Model for end-stage liver disease score were significant factors for concentration. Subsequently, the first four factors mentioned above entered into a stepwise multiple linear regression model (variance inflation factor CYP2C19 testing makes sense for precision medicine of Child–Pugh class C cirrhosis patients. The equation fits well and explains the 34.8% variety of concentrations (R2 = 0.348). In conclusion, it needs more cautious administration clinically due to no recommendation for Child–Pugh class C patients in the medication label. The adjustment of the administration regimen should be mainly based on the results of repeated therapeutic drug monitoring.
- 20 September 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (9) , 1130
Open AccessPredictors of Voriconazole Trough Concentrations in Patients with Child–Pugh Class C Cirrhosis: A Prospective Study
This prospective observational study aimed to clinically describe voriconazole administrations and trough concentrations in patients with Child–Pugh class C and to investigate the variability of trough concentration. A total of 144 voriconazole trough concentrations from 43 Child–Pugh class C patients were analyzed. The majority of patients (62.8%) received adjustments. The repeated measured trough concentration was higher than the first and final ones generally (median, 4.33 vs. 2.99, 3.90 mg/L). Eight patients with ideal initial concentrations later got supratherapeutic with no adjusted daily dose, implying accumulation. There was a significant difference in concentrations among the six groups by daily dose (p = 0.006). The bivariate correlation analysis showed that sex, CYP2C19 genotyping, daily dose, prothrombin time activity, international normalized ratio, platelet, and Model for end-stage liver disease score were significant factors for concentration. Subsequently, the first four factors mentioned above entered into a stepwise multiple linear regression model (variance inflation factor CYP2C19 testing makes sense for precision medicine of Child–Pugh class C cirrhosis patients. The equation fits well and explains the 34.8% variety of concentrations (R2 = 0.348). In conclusion, it needs more cautious administration clinically due to no recommendation for Child–Pugh class C patients in the medication label. The adjustment of the administration regimen should be mainly based on the results of repeated therapeutic drug monitoring.
- 19 February 2020
- Published by Taylor & Francis in Analytical Letters
- Vol. 53 (12) , 2002-2019
Determination of Risperidone and 9-Hydroxyrisperidone in Human Serum by Heart-Cutting Isocratic Two-Dimensional Liquid Chromatography
This study reports a novel heart-cutting two-dimensional high performance liquid chromatography (2D-LC) method with ultraviolet detection for the determination of risperidone and 9-hydroxyrisperidone in human serum. In this 2D system, a strong cation-exchange column was applied for the first dimensional (1D) separation to isolate the targets from the complex serum matrices, and a middle column was used to transfer the targets from the first dimension to the second dimension (2D) through a six-port valve. A reverse-phase C18 column was selected in the second dimension for further separation. An assistant pump was optimized to prevent the peak dispersion and the loss of resolution. This method has the advantages of high sensitivity by large injection volume, simple one-step sample preparation and short analysis time. A linear range between 5 and 146 ng/mL for risperidone and 7 and 200 ng/mL for 9-hydroxyrisperidone was achieved. All of the results showed that the coupling of ion-exchange with reversed-phase liquid chromatography had powerful separation capabilities for risperidone and 9-hydroxyrisperidone in human serum. The method exhibited good repeatability and recoveries and may be used as a reliable approach for therapeutic drug monitoring in clinical analysis.
- 19 February 2020
- Published by Taylor & Francis in Analytical Letters
- Vol. 53 (12) , 2002-2019
Determination of Risperidone and 9-Hydroxyrisperidone in Human Serum by Heart-Cutting Isocratic Two-Dimensional Liquid Chromatography
This study reports a novel heart-cutting two-dimensional high performance liquid chromatography (2D-LC) method with ultraviolet detection for the determination of risperidone and 9-hydroxyrisperidone in human serum. In this 2D system, a strong cation-exchange column was applied for the first dimensional (1D) separation to isolate the targets from the complex serum matrices, and a middle column was used to transfer the targets from the first dimension to the second dimension (2D) through a six-port valve. A reverse-phase C18 column was selected in the second dimension for further separation. An assistant pump was optimized to prevent the peak dispersion and the loss of resolution. This method has the advantages of high sensitivity by large injection volume, simple one-step sample preparation and short analysis time. A linear range between 5 and 146 ng/mL for risperidone and 7 and 200 ng/mL for 9-hydroxyrisperidone was achieved. All of the results showed that the coupling of ion-exchange with reversed-phase liquid chromatography had powerful separation capabilities for risperidone and 9-hydroxyrisperidone in human serum. The method exhibited good repeatability and recoveries and may be used as a reliable approach for therapeutic drug monitoring in clinical analysis.
- 30 August 2019
- Published by Wiley in Biomedical Chromatography
- Vol. 34 (1) , e4695
A novel and nonderivatization method for the determination of valproic acid in human serum by two‐dimensional liquid chromatography
A novel and robust two‐dimensional liquid chromatography with ultraviolet detection method (2D‐LC–UV) was developed and validated for high‐throughput determination of the concentrations of valproic acid (VPA) in human plasma. This 2D‐LC system was composed of a first‐dimensional LC column, a second‐dimensional LC column and an intermediate transfer column. The sample was directly injected into the 2D‐LC system after an easy protein precipitation treatment. After online preconcentration and primary separation by the first‐dimensional column, the target was captured by an intermediate column and then transferred to second‐dimensional column for analysis. The system transferred the target through “central cutting” mode whereby the drug peak was not subject to interference from the matrix. The analysis cycle time was completed within 7.0 min. Compared with other methods that have been developed, the analysis time was reduced and the operation was much easier without any derivatization. The calibration curve was linear over the 5.90–188.94 μg/ml range for the VPA concentrations. The intra‐day and inter‐day precisions were <5.6%. The recoveries were in the range from 95.2 to 98.0%. This method appears to be sensitive, precise, rapid and low‐cost for the quantification of VPA in serum sample.
- 30 August 2019
- Published by Wiley in Biomedical Chromatography
- Vol. 34 (1) , e4695
A novel and nonderivatization method for the determination of valproic acid in human serum by two‐dimensional liquid chromatography
A novel and robust two‐dimensional liquid chromatography with ultraviolet detection method (2D‐LC–UV) was developed and validated for high‐throughput determination of the concentrations of valproic acid (VPA) in human plasma. This 2D‐LC system was composed of a first‐dimensional LC column, a second‐dimensional LC column and an intermediate transfer column. The sample was directly injected into the 2D‐LC system after an easy protein precipitation treatment. After online preconcentration and primary separation by the first‐dimensional column, the target was captured by an intermediate column and then transferred to second‐dimensional column for analysis. The system transferred the target through “central cutting” mode whereby the drug peak was not subject to interference from the matrix. The analysis cycle time was completed within 7.0 min. Compared with other methods that have been developed, the analysis time was reduced and the operation was much easier without any derivatization. The calibration curve was linear over the 5.90–188.94 μg/ml range for the VPA concentrations. The intra‐day and inter‐day precisions were <5.6%. The recoveries were in the range from 95.2 to 98.0%. This method appears to be sensitive, precise, rapid and low‐cost for the quantification of VPA in serum sample.
- Open Access
- 25 April 2019
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 20 (1) , 19
Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
Tigecycline, with broad in vitro antibacterial activity, has been widely used off-label for nosocomial pneumonia caused by multi-drug resistant Acinetobacter baumannii (MDRAB). However, many concerns have been raised about the efficacy of tigecycline treatment as the inconsistent results from previous clinical studies. This retrospective study evaluated the outcome of adult patients with monomicrobial MDRAB nosocomial pneumonia treated with tigecycline between 2015 and 2017. Results. A total of 77 patients was eligible for this study, and the overall clinical success and 30-day survival rates were 70.03 and 70.13%, respectively, however, the microbiological eradication rate was relatively low (48%). Multivariate analysis indicated that shorter duration of tigecycline use associated with increased clinical failure, whereas higher CURB65 scores, mechanical ventilation and tigecycline resistant to MDRAB have significant association with 30-day mortality. Our results suggest that tigecycline is one of the potential choices for the treatment of hospital-acquired pneumonia caused by MDRAB, especially with a MIC≤2 mg/L. In addition, a longer duration of tigecycline treatment may be required to insure better clinical outcomes.
- 25 April 2019
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 20 (1) , 19
Open AccessClinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
Tigecycline, with broad in vitro antibacterial activity, has been widely used off-label for nosocomial pneumonia caused by multi-drug resistant Acinetobacter baumannii (MDRAB). However, many concerns have been raised about the efficacy of tigecycline treatment as the inconsistent results from previous clinical studies. This retrospective study evaluated the outcome of adult patients with monomicrobial MDRAB nosocomial pneumonia treated with tigecycline between 2015 and 2017. Results. A total of 77 patients was eligible for this study, and the overall clinical success and 30-day survival rates were 70.03 and 70.13%, respectively, however, the microbiological eradication rate was relatively low (48%). Multivariate analysis indicated that shorter duration of tigecycline use associated with increased clinical failure, whereas higher CURB65 scores, mechanical ventilation and tigecycline resistant to MDRAB have significant association with 30-day mortality. Our results suggest that tigecycline is one of the potential choices for the treatment of hospital-acquired pneumonia caused by MDRAB, especially with a MIC≤2 mg/L. In addition, a longer duration of tigecycline treatment may be required to insure better clinical outcomes.